Dendritic Cells Infiltrating Tumors Cotransduced with Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf) and Cd40 Ligand Genes Take up and Present Endogenous Tumor-Associated Antigens, and Prime Naive Mice for a Cytotoxic T Lymphocyte Response by Chiodoni, Claudia et al.
 
125
 
J. Exp. Med. 
 
Ó
 
 The Rockefeller University Press • 0022-1007/99/07/125/09 $5.00
Volume 190, Number 1, July 5, 1999 125–133
http://www.jem.org
 
Dendritic Cells Inﬁltrating Tumors Cotransduced with
Granulocyte/Macrophage Colony-stimulating Factor
(GM-CSF) and CD40 Ligand Genes Take Up and Present 
Endogenous Tumor-associated Antigens, and Prime Naive 
Mice for a Cytotoxic T Lymphocyte Response
 
By Claudia Chiodoni,
 
*
 
 Paola Paglia,
 
*
 
 Antonella Stoppacciaro,
 
‡ 
 
Monica Rodolfo,
 
*
 
 Mariella Parenza,
 
*
 
 and Mario P. Colombo
 
*
 
From the 
 
*
 
Department of Experimental Oncology, Istituto Nazionale per lo Studio e la Cura dei 
Tumori, 20133 Milan, Italy; and the 
 
‡
 
Department of Experimental Medicine and Pathology, 
University of Rome “La Sapienza,” 00100 Rome, Italy
 
Summary
 
We transduced BALB/c-derived C-26 colon carcinoma cells with granulocyte/macrophage
colony-stimulating factor (GM-CSF) and CD40 ligand (CD40L) genes to favor interaction of
these cells with host dendritic cells (DCs) and, therefore, cross-priming. Cotransduced cells
showed reduced tumorigenicity, and tumor take was followed by regression in some mice. In
vivo tumors were heavily infiltrated with DCs that were isolated, phenotyped, and tested in vitro
for stimulation of tumor-specific cytotoxic T lymphocytes (CTLs). BALB/c C-26 carcinoma
 
cells express the endogenous murine leukemia virus (MuLV) 
 
env 
 
gene as a tumor-associated anti-
gen. This antigen is shared among solid tumors of BALB/c and C57BL/6 mice and contains
two epitopes, AH-1 and KSP, recognized in the context of major histocompatibility complex
class I molecules H-2L
 
d
 
 and H-2K
 
b
 
, respectively. DCs isolated from C-26/GM/CD40L tu-
mors grown in (BALB/c 
 
3
 
 C57BL/6)F1 mice (H-2
 
d
 
3
 
b
 
) stimulated interferon 
 
g
 
 production by
both anti–AH-1 and KSP CTLs, whereas tumor-infiltrating DCs (TIDCs) of BALB/c mice
stimulated only anti–AH-1 CTLs. Furthermore, TIDCs primed naive mice for CTL activity as
early as 2 d after injection into the footpad, whereas double-transduced tumor cells required at
least 5 d for priming; this difference may reflect direct DC priming versus indirect tumor cell
priming. Immunohistochemical staining indicated colocalization of DCs and apoptotic bodies
in the tumors. These data indicate that DCs infiltrating tumors that produce GM-CSF and
CD40L can capture cellular antigens, likely through uptake of apoptotic bodies, and mature in
situ to a stage suitable for antigen presentation. Thus, tumor cell–based vaccines engineered to
favor the interaction with host DCs can be considered.
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B
 
one marrow–derived dendritic cells (DCs)
 
1
 
 are profes-
sional APCs that are critical for the initiation of im-
mune responses in vivo (1, 2). DCs take up antigens in the
peripheral tissues, and process and transport them to lym-
phoid organs for presentation to T cells. The maturation
and functions of DCs are tightly regulated by cytokines and
costimulatory signals.
Solid tumors are frequently infiltrated with inflammatory
cells, and the presence of DCs in the infiltrate has been
associated with a better prognosis in some human cancers
(3, 4). It has been demonstrated that tumor cells injected in
vivo are subjected to cross-priming by host DCs (5) that
capture, process, and present tumor-associated cellular anti-
gens to naive T cells during their encounter within the drain-
ing lymph node. Despite significant improvements in the
understanding of DC biology (2) and regulation of traffick-
ing by chemokines and chemokine receptors (6, 7), the in-
ability to isolate DCs from the tumors in sufficient number
for in vitro exhaustive analyses has hindered efforts to
 
1
 
Abbreviations used in this paper:
 
 DC, dendritic cell; MuLV, murine leuke-
mia virus; TAA, tumor-associated antigen; TIDC, tumor-infiltrating den-
dritic cell; TUNEL, terminal deoxynucleotidyl transferase–mediated
dUTP nick end labeling. 
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define the precise events involved in DC local uptake of
cellular antigens and in local DC maturation to an antigen-
presenting stage. However, studies have implicated capture
of apoptotic bodies (8–10) or endocytosis of heat shock
protein–epitope complexes (11, 12) in DC uptake of cellu-
lar antigens.
We previously showed that cytokine-transduced C-26
colon carcinoma nodules are infiltrated by DCs, whose
number and function depend on the transduced cytokine
(13). Among the cytokines analyzed, IL-4 induced the re-
cruitment of the highest number of DCs into the tumor
mass, as detectable by immunohistochemistry. However, the
number of tumor-infiltrating DCs (TIDCs) isolated from
the tumor mass was not sufficient for extended in vitro in-
vestigation. Thus, attempts to correlate number and func-
tion were limited to a delayed-type hypersensitivity (DTH)
assay showing that when injected into the ear pinna, TIDCs
from tumors transduced with GM-CSF stimulated, whereas
TIDCs from C-26/IL-4 tumors inhibited, DTH reaction
to dinitrofluorobenzene (DNFB [13]). In the present study,
we cotransduced C-26 tumor cells with the genes encod-
ing soluble GM-CSF and a membrane-bound molecule,
CD40L, based on the observation that soluble and cell–cell
contact signals often synergize in cell activation (14).
GM-CSF induces proliferation and maturation of hema-
topoietic cells, and has been shown to stimulate DC accessory
properties and to enhance the immune response initiated by
these cells (15, 16).
The CD40/CD40L interaction plays a critical role in
cell-mediated immunity (17) and in proliferation and acti-
vation of APCs, as shown for B cells (18), monocytes, and,
more recently, DCs (19–21). Ligation of CD40 on mono-
cytes and DCs results in the secretion of several cytokines,
including IL-1, IL-6, IL-12, and TNF-
 
a
 
.
We show here that C-26/GM/CD40L tumors are heavily
infiltrated by DCs that are able to capture and present en-
dogenous tumor antigen(s) to specific CTL clones and to
prime naive mice for a CTL response against the parental
tumor. These findings point to the potential of tumor cell
vaccines designed to exploit the DC functional bridge be-
tween T lymphocytes and the cell vaccine.
 
Materials and Methods
 
Mice and Tumors.
 
8–10-wk-old female BALB/c (H-2
 
d
 
) and
(BALB/c 
 
3
 
 C57BL/6)F1 (H-2
 
d
 
3
 
b
 
) hybrid mice were purchased
from Charles River and maintained at the Istituto Nazionale Tumori
under standard conditions according to institutional guidelines.
C-26 is a murine colon adenocarcinoma cell line derived from
BALB/c mice treated with 
 
N
 
-nitroso-
 
N
 
-methylurethane. Tumor
cells were cultured in DMEM (GIBCO BRL) supplemented
with 10% FCS (GIBCO BRL). Tumorigenic activity of control
and transduced C-26 cells was assayed in mice injected subcuta-
neously in the left flank with 5 
 
3 
 
10
 
4
 
 cells in 0.2 ml. Tumor
growth and size were recorded twice each week.
 
Vector Construction and Retroviral Infection.
 
The cDNAs for
GM-CSF and CD40L were cloned by reverse transcription PCR:
GM-CSF cDNA was obtained from Con A–stimulated murine
blasts using GM-CSF–specific primer ends modified to include 5
 
9
 
and 3
 
9
 
 EcoRI and BamHI sites, respectively. The resulting 517-bp
insert was ligated into EcoRI and BamHI of retroviral vector
LXSN (22) to obtain vector LmGMSN. CD40L cDNA was am-
plified from EL4 thymoma cells using specific primer ends con-
taining 5
 
9
 
 and 3
 
9
 
 HpaI and XhoI sites, respectively, and the 817-bp
insert was cloned into HpaI and XhoI sites of LXSH to obtain
vector LmCD40LSH.
Retroviral vectors were transfected into the gp
 
1
 
E86 packag-
ing cell line by standard calcium phosphate coprecipitation, and the
48-h culture supernatant was used to infect the amphotropic
Am12 or PA317 packaging cell line. Infected Am12 and PA317
cells were selected with G418 and hygromycin, respectively, and
used to generate helper-free virus–containing supernatants.
C-26 target cells were infected by four cycles of exposure to un-
diluted supernatant for 2 h in the presence of polybrene (8 mg/ml).
At 48 h after infection, cells were diluted and selected in G418 or
hygromycin. Bulk cultures and single resistant colonies were ex-
panded and screened by ELISA for GM-CSF production, and by
FACS
 
®
 
 analysis for CD40L expression. Limiting dilution cloning
was used to obtain optimal levels of CD40L expression.
 
Flow Cytometry.
 
Expression of CD40L on transduced cell lines
was assayed by flow cytometry after conventional staining with
biotin-conjugated anti-CD40L mAb, clone MR1, followed by
STREP-PE (PharMingen). The phenotype profile of tumor-
infiltrating leukocytes was analyzed by double immunostaining
using the following mAbs: FITC-conjugated anti-CD4, PE-con-
jugated anti-CD8, PE-conjugated anti-CD11c, FITC-conju-
gated anti-B220, and isotype controls (all from PharMingen).
Surface markers on TIDCs were detected using the following
mAbs: M1/42, anti-MHC I; B21.2, anti-MHC II; 53.6.72, anti-
CD8; SER4; 1G10, anti-B7.1; GL1, anti-B7.2; and isotype-
matched mAbs of unrelated specificity as controls. Analysis was
performed on a FACScan
 
®
 
 (Becton Dickinson). Data were col-
lected on 5,000–10,000 viable cells and analyzed using Lysis II
software.
 
Morphological Analysis and Immunocytochemistry.
 
Tumor frag-
ments, tumor-draining lymph nodes, and spleens were embedded
in OCT compound (Miles, Inc.), snap-frozen in liquid nitrogen,
and stored at 
 
2
 
80
 
8
 
C. Immunochemical analysis using the peroxi-
dase-antiperoxidase (PAP) method was performed as described
(23). In brief, 5-
 
m
 
m cryostat sections were fixed in acetone and
immunostained with rat anti–mouse mAb against CD45 (M1/
9.3.4.HL2 hybridoma, T200), CD8 (53.6.72 hybridoma, Lyt2),
CD4 (GK1.5 hybridoma, L3T4), Mac-3 (M37/84 hybridoma,
TIB168) (all from American Type Culture Collection), DEC-
205 (NLDC-145; provided by Ralph Steinman, The Rockefeller
University, New York), and GR-1 (RB6-8C5 hybridoma; Phar-
Mingen). Sections were preincubated with rabbit serum and se-
quentially incubated with optimal dilutions of primary antibodies,
rabbit anti–rat IgG (Zymed Laboratories, Inc.), and rat PAP (Abbot
Laboratories). Each incubation step lasted 30 min and was fol-
lowed by a 10-min wash in TBS. Sections were then incubated
with 0.03% H
 
2
 
O
 
2
 
 and 0.06% 3,3
 
9
 
-diaminobenzidine (BDH
Chemicals) for 2–5 min, washed in tap water, and counterstained
with hematoxylin. The number of immunostained cells was de-
termined by light microscopy at 400
 
3
 
 magnification in five fields
on a 1-mm
 
2
 
 grid, and is given as cells/mm
 
2
 
 (mean 
 
6 
 
SD).
For in situ TUNEL (terminal deoxynucleotidyl transferase
[TdT]-mediated dUTP nick end labeling) staining, tumor cryo-
stat sections (5 
 
m
 
m) were fixed in acetone, conventionally immu-
noperoxidase stained with anti–DEC-205 using biotinylated sec-
ondary antibody/streptavidin-horseradish peroxidase, and developed
in red by aminoethylcarbazole (AEC; Dakopatts). Sections were 
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then fixed with 4% paraformaldehyde for 20 min at room temper-
ature, washed twice in PBS, permeabilized with 0.1% Triton X-100
and 0.1% sodium citrate for 2 min on ice, and washed twice with
TBS. The labeling of 3
 
9
 
-OH fragmented DNA ends (TUNEL)
was carried out using an in situ apoptosis detection kit (FragEL kit;
Calbiochem). Labeled ends were detected with strepto-alkaline
phosphatase (AP; Dakopatts). 5-bromo-4-chloro-3-indolyl-phos-
phate (BCIP; Dakopatts) was used as colorimetric substrate (black
stain). Control tissue sections were prelabeled with isotype-matched
irrelevant mAbs and treated for TUNEL staining without TdT.
 
Isolation of TIDCs.
 
Tumor cells were implanted subcutane-
ously in the left flank at 5 
 
3 
 
10
 
4
 
 cells/mouse, and tumors were
surgically removed 13–25 d after implantation when they reached
a mean diameter of 0.6–1.2 cm. Tumor masses were perfused
with collagenase D (Boehringer Mannheim) solution (400 U/ml),
gently minced into small pieces, and incubated in collagenase so-
lution for 45–60 min at 37
 
8
 
C. After gentle pipetting, the fine sus-
pension was washed several times with DMEM, and cells were
seeded on 6-well plates at 0.7 
 
3 
 
10
 
6
 
 cells/ml and incubated over-
night to allow adherence of tumor cells to the plastic. The fol-
lowing day, nonadherent cells were collected and purified using
CD11c
 
1
 
 microbeads (MiniMacs
 
®
 
; Miltenyi Biotec GmbH) and
used for subsequent experiments.
 
IFN-
 
g
 
 Production by C-26–specific CTL Clones.
 
The generation
and maintenance of anti-C26 CTL clone E/88 specific for murine
leukemia virus (MuLV) 
 
env-
 
derived peptide 423–431 SPSYVYHQF
(24) has been described previously (25). CTL 9A/89 recognizes
C-26–specific tumor-associated antigen (TAA) 9A in association
with H-2K
 
d 
 
(26). The CTL line TG905 was obtained from
popliteal lymph node cells repeatedly restimulated in vitro with
the MC38 (H-2
 
b
 
) colon carcinoma cells. TG905 cells recognize
MC38 cells and its 
 
env
 
-derived peptide, 574–581 KSPWFTTL
(27), but not C-26 cells or AH-1 peptide. CTL clones or lines
(10
 
5
 
 lymphocytes/well) were incubated with stimulating cells
(10
 
5
 
 cells/well or serial dilutions) or peptides (1 
 
m
 
g/ml) in 96-well
plates for 24 h. Supernatants were assayed for IFN-
 
g
 
 content by
specific ELISA (PharMingen).
 
Mixed Lymphocyte Tumor Culture and Cell-mediated Cytotoxicity.
 
Mixed lymphocyte tumor culture (MLTC) was performed in
RPMI 1640 medium (Hyclone) supplemented with 10% FCS
(Hyclone). Lymphocytes from popliteal lymph nodes of mice in-
jected into the right footpad with irradiated tumor cells or TIDCs
were used as responder cells. Stimulators were C-26 cells inacti-
vated with 
 
g
 
-irradiation (2,000 rad) or peptides (1 
 
m
 
g/ml). Re-
sponders and stimulators were suspended to 2.5 
 
3 
 
10
 
5
 
 and 2.5 
 
3
 
10
 
4 
 
cells/ml, respectively, mixed in a total volume of 2 ml in 24-
well plates (Costar Corp.), and cultures were incubated in a hu-
midified atmosphere of 5% CO
 
2
 
 in air. In cell-mediated cytotox-
icity (CMC) assays, C-26 cells were the specific target and P815
plasmacytoma cells (DBA/2) were the negative control for C-26
tumor–specific lysis.
 
Results
 
In Vivo Tumorigenicity of GM-CSF– and CD40L-trans-
duced C-26 Colon Carcinoma Cells.
 
C-26 colon carcinoma
cells were transduced with retroviral vectors carrying
GM-CSF and CD40L genes together with selectable mark-
ers, neomycin and hygromycin, respectively.
Clones obtained by limiting dilution from antibiotic-
resistant bulk cultures were screened for GM-CSF produc-
tion by ELISA, and for expression of CD40L by FACS
 
®
 
analysis. Two clones producing the same amount of
GM-CSF (10–15 ng/ml from 10
 
6
 
 cells in 48 h) were selected
among those obtained from single GM-CSF– and double
GM-CSF/CD40L–transduced cells. Similarly, clones with
the highest mean of CD40L expression were chosen from
C-26/CD40L and C-26/GM/CD40L cells for subsequent
experiments (data not shown).
To assess the effect of GM-CSF and/or CD40L trans-
duction on tumor growth, BALB/c mice were injected
subcutaneously with transduced or parental C-26 cells. Al-
though all mice injected with C-26 or C-26/GM cells de-
veloped fast-growing tumors and were killed within 3 wk
at the first sign of distress, 22 and 40% of animals injected
with C-26/CD40L and C-26/GM/CD40L cells, respec-
tively, remained tumor-free for the entire observation period
(3 mo). Some of the double-transduced tumors regressed
after an initial outgrowth, eventually resulting in 70%
tumor-free mice (Fig. 1). Cell depletion by specific anti-
bodies indicated that both CD8
 
1
 
 T cells and GR1
 
1
 
 PMNs
were required for tumor rejection (data not shown).
 
Leukocyte Infiltration of GM-CSF– and CD40L-expressing
Tumors.
 
To investigate the effect of CD40L and GM-CSF
transduction on DC recruitment, we examined tumor infil-
trates by flow cytometry. Tumors injected subcutaneously
and surgically removed 15–25 d later were perfused with
collagenase D solution, and the resulting cell suspension was
incubated overnight to let tumor cells adhere to the plastic.
The following day, nonadherent cells were collected and
stained for FACS
 
®
 
 analysis. Although C-26 parental tumors
were not infiltrated, GM-CSF–transduced tumors had nu-
merous granulocytes (data not shown) and some (5–10%)
CD11c
 
1
 
 DCs. Some CD40L-expressing tumors were char-
acterized by the presence of B cells (CD11c
 
2
 
B220
 
1
 
) and
more numerous DCs (CD11c
 
1
 
B220
 
2
 
, range 7–20%; Fig. 2).
In the double-transduced tumors, the percentage of
CD11c
 
1
 
 cells ranged between 5 and 40%, but some tumors
clearly showed that 
 
.
 
20% of infiltrating cells stained with
CD11c. Immunohistology with mAb to DEC-205 con-
firmed these data and revealed the highest percentage of
Figure 1. In vivo tumorigenicity of C-26 cells and genetically modi-
fied variants. Cells (5 3 104) were injected subcutaneously into the left
flank of female BALB/c mice (n 5 35). s, C-26; u, C-26/GM; d,
C-26/CD40L; j, C-26/GM/CD40L. *P , 0.01; **P , 0.05, as deter-
mined using the Mann-Whitney test to compare transduced cell lines
with the parental C-26 cells. 
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DCs in the five double-transduced tumors positive for
membrane CD40L expression (Table I), suggesting a role
for local expression of CD40L in attracting or maintaining
DCs in the tumor. Seven other double-transduced tumors
lost CD40L expression, likely due to in vivo methylation
and thus inactivation of the retroviral promoter (LTR)
driving the transgene expression (28).
In the presence of both CD40L and GM-CSF, DCs rep-
resented between 20 and 40% of total CD45
 
1
 
 leukocytes,
thus allowing their in vitro isolation and purification using
CD11c-conjugated beads.
GM-CSF expression by transduced tumors is reflected in
spleen hypertrophy due to increased spleen hematopoiesis
characterized by the presence of mixed colonies (mega-
karyocytes and granulocytes) throughout the white pulp.
No such spleen hypertrophy was observed in mice injected
with C-26/CD40L cells. In spleen of mice injected with
GM-CSF– and CD40L-coexpressing tumor cells, the com-
position of the colonies showed a shift toward enrichment
with eosinophils (data not shown).
 
Phenotypic Characterization of TIDCs.
 
Expression of sur-
face markers on TIDCs from C-26/GM/CD40L tumors was
assessed by immunostaining and subsequent FACS
 
®
 
 analysis.
The CD11c
 
1
 
 population showed a phenotypic profile char-
acteristic of differentiated or mature DCs, i.e., high surface
expression of MHC class I and class II proteins and substan-
tial expression of costimulatory molecules such as CD80
(B7.1) and CD86 (B7.2) (Fig. 3); such mature phenotype
was confirmed by stimulatory activity of TIDCs in MLR
(data not shown).
Prolonged in vitro culture of collagenase-digested C-26/
GM/CD40L tumor cell suspension revealed aggregation of
cells with DC morphology in characteristic clusters (Fig. 4
shows one such cluster at day 3) and survival of these cells
on tumor layer for up to 7 d.
 
Functional Characterization of TIDCs; Antigen Uptake at the
Tumor Site.
 
The abundance of DCs infiltrating the C-26/
GM/CD40L tumors enabled analyses to address whether
such DCs take up and present tumor cellular antigens. The
 
env
 
 gene of the endogenous ecotropic MuLV is expressed by
C-26 colon carcinoma cells as an immunodominant TAA
that contains the L
 
d
 
-restricted peptide, AH-1 (amino acids
423–431; reference 24). In addition, C-26 cells express at
least one additional, to date uncloned, TAA recognized by
the CTL clone 9A/89 in an H-2K
 
d
 
–restricted manner (26).
The MuLV
 
 env
 
 is also expressed by MC38 (H-2
 
b
 
) colon
carcinoma and is recognized by the TG905 CTL line
through the KSP peptide restricted in K
 
b 
 
(27).
Specific T cell clones and line were used to test whether
TIDCs isolated from C-26/GM/CD40L tumors can present
endogenous TAAs. CTL clones maintained in culture with
IL-2 readily produce IFN-
 
g
 
, without the need for APCs or
costimulatory signals, when stimulated with tumor cells. To
rule out the possibility that tumor cells contaminating the
TIDC preparation were responsible for CTL stimulation,
the experiment was performed in (BALB/c 
 
3
 
 C57BL/6)F1
hybrids (Table II).
CTL clones and line were cocultured overnight with ei-
ther TIDCs from C-26/GM/CD40L grown into F1 mice,
or splenic DCs from naive mice. As control for CTL re-
striction, C-26 (H-2
 
d) and MC38 (H-2b) tumor cells were
used. TIDCs (H-2d/b) from F1 mice were able to stimulate
both H-2d (E/88 and 9A/89) and H-2b (TG905) CTLs,
whereas C-26 stimulated H-2d but not H-2b CTLs and
MC38 stimulated TG905 cell line but not E/88 and 9A/89
CTL clones. Accordingly, TIDCs from C-26/GM/CD40L
grown into BALB/c mice stimulated anti–AH-1 but not
anti-KSP CTLs (not shown). The lower level of IFN-g
produced by stimulation with TIDCs compared with tu-
mor cells (or the peptide alone) might rest in the fact that
few TIDCs are likely to be loaded with the specific anti-
gen, while all tumor cells express the TAAs. Thus, the C-26
MuLV env-derived antigens are taken up and processed by
host DCs most probably at the tumor site.
Uptake of Apoptotic Cells. Immunohistological double
staining for DCs (with anti–DEC-205 mAb) and apoptotic
cells (TUNEL) revealed the presence of apoptotic bodies en-
gulfed by DCs (Fig. 5) in the region outside necrotic areas.
Figure 2. FACS® analysis of leukocyte infiltrate in tumors. (A) C-26/
GM; (B) C-26/CD40L; (C) C-26/GM/CD40L. Tumor masses were
surgically removed 15 d after implantation, then perfused with collage-
nase D solution, gently minced, and incubated in collagenase solution for
45–60 min at 378C. After gentle pipetting and washing the suspension
with DMEM several times, cells were seeded on 6-well plates at 0.7 3
106 cells/ml and incubated overnight to allow tumor cell adherence to the
plastic. Nonadherent cells were collected, double-labeled with CD8-PE/
CD4-FITC (left) or CD11c-PE/B220-FITC (right), and analyzed by
flow cytometry. Quadrants were set using isotype-matched antibodies as
controls (not shown).129 Chiodoni et al.
Although the tumor cell origin of such condensed nuclei re-
mains to be proven, the micrographs together with the func-
tional data strongly suggest that the uptake of apoptotic bod-
ies most likely underlies cross-priming, consistent with results
in a model of influenza virus–induced apoptosis (8, 10).
Rapid In Vivo CTL Priming of Naive Mice. To assess the
ability of TIDCs to prime a specific CTL response in vivo,
CD11c1-enriched TIDCs or C-26/GM/CD40L tumor cells
were injected in the footpad of naive BALB/c mice, popliteal
lymph nodes were removed 5 d later, and lymphocytes were
cultured in vitro with C-26 cells or AH-1–specific peptide
and tested after 6 d for CTL activity. Lymphocytes from mice
injected with TIDCs from the CD11c1-enriched fraction
primed mice to elicit specific CTLs against C-26 tumor
cells or AH-1–pulsed P815 cells (Fig. 6, A and B). C-26/
GM/CD40L tumor cells also induced a CTL response, al-
though to a lesser extent than TIDCs. When the time
allowed for in vivo priming was reduced from 5 to 2 d,
lymphocytes collected from the nodes of mice primed with
Table I. Immunohistology of C-26/GM/CD40L Double-transduced Tumors
Mouse no.
Expression
of CD40L
on tumor Necrosis CD45 CD4 CD8 Mac-3 GR DEC-205
IL2551#20 1 433 6 91* 19 6 63  6 5 283 6 30 85 6 30 57 6 16 (15%)‡
IL2551#30 1 511 6 100 39 6 19 19 6 10 168 6 35 239 6 47 46 6 16 (10%)
IL2552#3 11 519 6 51 83 6 17 55 6 13 65 6 12 334 6 151 130 6 68 (25%)
IL2552#10 11 630 6 91 9 6 52  6 2 176 6 35 389 6 101 54 6 10 (9%)
IL2553#3 1 429 6 16 7 6 51  6 2 199 6 17 ND 49 6 19 (11%)
IL2550#2 11 382 6 67 14 6 63  6 1 ND 180 6 5 36 6 9 (10%)
IL2550#10 11 428 6 91 30 6 23 17 6 15 195 6 15 131 6 19 37 6 20 (9%)
IL2550#20 1 414 6 121 35 6 15 6 6 5 164 6 35 149 6 17 56 6 13 (13%)
IL2551#0 2 765 6 23 49 6 5 11 6 3 342 6 83 230 6 21 61 6 30 (8%)
IL2552#2 1 111 559 6 17 71 6 5 59 6 11 100 6 23 191 6 30 105 6 4 (19%)
IL2550#3 11 532 6 45 26 6 11 8 6 5 114 6 16 108 6 18 61 6 56 (12%)
IL2550#30 1 567 6 110 80 6 40 7 6 3 225 6 29 223 6 20 23 6 10 (4%)
IL2551#10 1 111 525 6 50 129 6 18 121 6 17 74 6 12 118 6 13 200 6 30 (38%)
IL2551#2 11 1 452 6 27 37 6 17 31 6 15 115 6 27 169 6 25 103 6 78 (29%)
IL2553#20 1 Regressing 677 6 55 156 6 100 131 6 53 191 6 15 100 6 36 140 6 21 (21%)
*Mean no. of cells/mm2 6 SD positive for immunostaining.
‡Percentage of DEC-2051 cells among the CD451 leukocytes.
Figure 3. Phenotypic analysis of C-26/GM/CD40L TIDCs. DCs were
purified using CD11c-conjugated microbeads. Sorted cells were double-
stained for FACS® analysis as follows: CD11c-PE/biotinylated MHC I (A),
CD11c-PE/MHC II (B), CD11c-PE/B7.1 (C), and CD11c-PE/B7.2 (D).
Unlabeled mAbs were detected with mouse-FITC. Isotype-matched anti-
body controls were used to set quadrants (not shown).
Figure 4. TIDC clusters after 3 d of in vitro culture on GM-CSF and
CD40L cotransduced C-26 cells. After tumor mass digestion, the cellular
suspension was seeded in 6-well plates at 0.7 3 106 cells/ml; at day 3, non-
adherent cells were collected and gently cytospun onto glass slides to avoid
cluster disaggregation, then stained with Neat Stain kit (International PBI)
(original magnification: 3400).130 Uptake and Cross-presentation of Tumor Antigens
TIDCs 2 d earlier and restimulated in vitro with the spe-
cific AH-1 peptide showed a CTL response against C-26
cells, whereas those from mice primed with C-26/GM/
CD40L did not (Fig. 6 B). A likely explanation for such
difference is that TIDCs are able to migrate immediately to
the draining lymph node upon injection, whereas tumor
cells should be first destroyed and then antigen loaded onto
host DCs to allow T cell priming.
Discussion
Tumor cells can be genetically modified to produce cyto-
kines and/or costimulatory molecules that improve their
immunogenicity, thus providing new testable cellular vac-
cines. These vaccines are usually designed to act directly on
T cells, providing signals for the activation (e.g., IL-2) and/or
costimulation (e.g., B7.1) of these cells. Based on this ratio-
nale, it should be possible to render the tumor cells “mock”
APCs that directly interact with and activate tumor-specific
Table II. IFN-g Production (ng/ml) from Anti-C26 CTL Clones and Anti-KSP CTL Line
Stimulators
(H-2 haplotype) Cell no.
Experiment 1 Experiment 2
9A/89
(H-2Kd)
E/88*
(H-2Ld)
TG905*
(H-2Kb)
E/88*
(H-2Ld)
TG905*
(H-2Kb)
TIDCs (H-2d/b)1 0 5 13.57 17.64 16.61 19.95 26.93
5 3 104 — — — 11.35 15.30
2.5 3 104 — — — 4.60 11.35
1.25 3 104 — — — 2.51 8.33
C-26 (H-2d)1 0 5 60.7 101 0 88.1 1.2
5 3 104 — — — 31.12 0
2.5 3 104 — — — 20.42 0
1.25 3 104 — — — 16.47 0
MC38 (H-2b) 105 — 0 78.6 0 87.2
5 3 104 — — — 0 19.95
2.5 3 104 — — — 0 16.63
1.25 3 104 — — — 0 14.3
Spleen DCs‡ 105 0.3 0.3 0 0 0
*E/88 and TG905 recognize different peptides (H-2d and H-2b restricted, respectively) of the same MuLV env-encoded antigen.
‡DCs purified from spleen of naive mice.
Figure 5. Apoptotic bodies within TIDCs. Double staining with
DEC-205 and TUNEL reveals DCs engulfed with apoptotic bodies and
blebs in C-26/GM/CD40L tumors (original magnifications: 3400; in-
serts: 31,000).
Figure 6. CTL activity after in vivo priming of BALB/c mice with
CD11c1-enriched fraction of TIDCs (j) or C-26/GM/CD40L control
tumor cells (h). 105 cells were injected in the footpad of naive BALB/c
mice; after 5 (top panels) or 2 d (bottom panels), popliteal lymph nodes
were removed. Lymphocytes were cultured in vitro with the AH-1–spe-
cific peptide and tested 6 d later for CTL activity.131 Chiodoni et al.
lymphocytes. Clinical application of such cellular vaccines
requires an autologous setting or HLA-matched cell lines.
While autologous application is difficult, since it requires
tumor cell cultures from every patient for both gene trans-
duction and immunological follow-up, the use of allogeneic
cell lines provides the advantage of vaccines with well-
characterized tumor antigen, MHC, and adhesion molecules,
as well as a constant amount of cytokine released. These
parameters may provide a standard reagent for clinical stud-
ies. Either syngeneic or allogeneic tumor cells expressing a
common TAA are processed by host APCs such that TAA-
derived peptides are presented in association with host MHC
in both cases (5). In light of these considerations, we fo-
cused on the interaction of the cellular vaccine with profes-
sional APCs, i.e., DCs, in an effort to favor the in vivo
cross-priming.
To design such a vaccine, we began by genetically modify-
ing C-26 colon carcinoma cells to express GM-CSF and
CD40L, two critical factors for DC maturation and activation.
GM-CSF has shown potent immunostimulatory activity
that leads to long-lasting, specific antitumor immunity in
some tumor models (29, 30) but not in others (31, 32), prob-
ably due to differences in tumor type or amount of cytokine
released (33). Our preliminary experiments indicate that
GM-CSF enhanced tumor immunogenicity, protecting mice
from a subsequent challenge with live parental C-26 tumor
cells (our unpublished results) without impairing growth of
transduced cells. It seems likely that GM-CSF has no effect
on the early immune response, but instead plays a crucial role
in the T cell–mediated response by recruiting and activating
APCs (1); GM-CSF can also substitute for IFN-g in inducing
late regression of C-26 cells transduced with IL-12 genes and
injected into IFN-g knockout mice (34).
The other component of our double-transduced cellular
vaccine, CD40L, has been shown to play a central role in
inducing an immune response through its interaction with
CD40 (17, 21), although its antitumor effect has only re-
cently been described in a few tumor models. Grossmann
et al. (35) reported that constitutive expression of CD40L
on a weakly immunogenic murine tumor (neuro-2a) delays
the growth of coinjected parental cells and protects mice
from subsequent challenge with parental neuro-2a cells.
The antitumor effect was abrogated by in vivo depletion of
CD81 cells. Those investigators also detected increased ex-
pression of markers such as CD25 and CD86 in splenocytes
from mice injected with CD40L-transfected cells, but
B2201 cells were the most abundant subset. Similarly, we
noted the overgrowth of B2201 cells when CD40L- and
GM-CSF/CD40L–transduced C-26 cells were each cocul-
tured in vitro with naive splenocytes (not shown).
Transduction of CD40L into P815 tumor cells completely
inhibited tumor take; there, CD40L activated macrophages
to release IL-12, which in turn stimulated NK activity (36).
In C-26 cells transduced only with CD40L, tumor take
was abrogated in a small fraction of injected mice (22%),
whereas cotransduction of CD40L with GM-CSF led to at
least an additive effect in inducing a late regression of incip-
ient tumors. It is possible that CD40L activates an early
mechanism of tumor killing, probably mediated by neutro-
phils, that counters tumor onset and thereby allows suffi-
cient time for GM-CSF indirect activation, via DCs, of T
cells. Tumor regression depended on CD81 T cells and
granulocytes, but not on CD41 T cells. As suggested previ-
ously (37–41), it is likely that CD40L substitutes the need
for CD4 Th cells in cross-priming.
In our model, GM-CSF and CD40L appear to be neces-
sary and sufficient to promote the recruitment of DCs and to
activate them at the tumor site. The phenotype of TIDCs is
consistent with mature DCs, since they express high levels
of MHC class I and class II, and of costimulatory molecules
such as B7.1 and B7.2. This phenotype and the stimulatory
activity in MLR correlate with antigen-presenting func-
tion; indeed, DCs isolated from C-26/GM/CD40L tumor
tissues have taken up tumor antigens in vivo, and can present
them to tumor-specific T cells and prime T lymphocytes
upon injection into naive mice. GM/CD40L-transduced
tumor cells are also able to induce a specific CTL response,
although TIDCs do so more rapidly, suggesting a direct
DC priming of T cells. However, in our transfer experi-
ment, the question of whether TIDCs prime host T cells
directly or are destroyed by host effector cells after which
antigens are taken up and represented by host APCs (42)
has not yet been investigated, and further experiments are
needed to address this issue.
TIDCs purified from C-26/GM/CD40L tumors grown
in BALB/c 3 C57BL/6 hybrid mice can present the en-
tire known repertoire of C-26 cell TAAs (the Ld- and
Kb-restricted epitopes from env-1 and the Kd-restricted
epitope of an unidentified cellular gene).
The functional data on in vivo cross-priming, together
with immunohistology showing that TIDCs are engulfed
with apoptotic bodies, point to the role of apoptosis as a
source of cellular antigens in a tumor model (8, 9).
Unlike several other models that relied on the use of sur-
rogate tumor antigens such as b-galactosidase (43), influ-
enza nucleoprotein (5), or OVA (44) to prove presentation
of exogenous antigens in the context of class I MHC, our
model represents the first direct evidence that endogenous
tumor antigens are taken up and processed by host DCs in
an MHC I–restricted fashion directly at the tumor site.
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